Oncoc4, Inc.
Clinical trials sponsored by Oncoc4, Inc., explained in plain language.
-
New Dual-Action drug targets tumors in early trial
Disease control Recruiting nowThis study tests a new drug called AI-081 in people with advanced solid tumors that have spread. The drug is designed to block two cancer pathways (PD-1 and VEGF) at once. The main goals are to find the safest dose and check for side effects. About 387 adults will take part in th…
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 07:49 UTC
-
New hope for lung cancer patients: experimental drug aims to outlast chemo
Disease control Recruiting nowThis study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that got worse after prior immunotherapy. About 630 adults will be randomly assigned to receive either the new drug or chemo every…
Phase: PHASE3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
New drug ONC-841 enters early human testing for advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug, ONC-841, in about 72 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive the drug by IV, either alone or with standard trea…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC